In our rearview mirror is a ten-year stretch of experimentation. What looms ahead is the rewriting of healthcare's rules.
Whoever's closest to the consumer will be the gatekeeper of the industry.
A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.
Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.
Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.
How pharmaceutical companies can better define, measure, and deliver value to patients.
What's around the bend for healthcare venture capital in 2018? We talk Amazon, good and bad M&A, and hitting the investment peak.
As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.
How a “sticky” consumer experience could help control the drain of high-cost chronic disease drugs.
Direct-purchase agreements are being floated as a price-control strategy. But how is value defined? And when might low cost come at the expense of true value?